Search results for "Pouchitis"

showing 5 items of 5 documents

Natural history of cytomegalovirus infection in a series of patients diagnosed with moderate-severe ulcerative colitis

2011

AIM: To evaluate the natural history of human cytomegalovirus (HCMV) infection in a series of 28 ulcerative colitis patients in whom the search for HCMV was positive. METHODS: A series of 85 patients with moderate-severe ulcerative colitis flare-up were evaluated for a HCMV search by performing a haematoxylin and eosin stain, immunohistochemical assay and nested polymerase chain reaction on rectal biopsies. Among 85 screened patients (19 of whom were steroid resistant/dependant), 28 were positive for HCMV; after remission the patients were followed up clinically and histologically. RESULTS: Among the 22 patients with complete follow-up, in 8 (36%) patients HCMV-DNA persisted in the intestin…

AdultMaleHuman cytomegalovirusmedicine.medical_specialtyBrief ArticlevirusesCongenital cytomegalovirus infectionCytomegalovirusGastroenterologyRecurrenceInternal medicinemedicineHumansProspective StudiesColitisProspective cohort studyAntigens ViralAcute colitisAgedbusiness.industryRemission InductionGastroenterologyvirus diseasesGeneral MedicinePouchitisMiddle Agedbiochemical phenomena metabolism and nutritionmedicine.diseaseUlcerative colitisCytomegalovirus InfectionsDNA ViralImmunologyColitis UlcerativeFemalebusinessNested polymerase chain reactionWorld Journal of Gastroenterology
researchProduct

Prospective study of morphologic and functional changes with time in the mucosa of the ileoanal pouch: functional appraisal using transmucosal potent…

1998

PURPOSE: This study was undertaken to investigate the morphologic and functional changes with time in the mucosa of the ileoanal pouch. METHODS: A morphologic study by histopathologic analysis, mucosal morphometry, and mucin histochemistry and a functional study by analysis of transmucosal potential difference were performed in 27 patients with an ileoanal J-pouch after restorative proctocolectomy for ulcerative colitis. In 19 patients with a normal ileoanal pouch, two prospective follow-up analyses were performed after median functional pouch times of 14 and 39 months. We also evaluated eight patients with the diagnosis of pouchitis (median follow-up, 52.5 months). RESULTS: In the normal i…

AdultMalemedicine.medical_specialtyColonmedicine.medical_treatmentRectumGastroenterologyMembrane PotentialsAtrophyInternal medicinemedicineHumansProspective StudiesVillous atrophyIntestinal MucosaProspective cohort studyAgedInflammationProctocolectomybusiness.industryHistocytochemistryProctocolectomy RestorativeGastroenterologyMucinsGeneral MedicinePouchitisMiddle Agedmedicine.diseaseUlcerative colitismedicine.anatomical_structureColitis UlcerativeFemalePouchbusinessDiseases of the colon and rectum
researchProduct

Pouchitis: A tridimensional view

2016

The preferred surgical treatment of ulcerative colitis (UC) and familial adenomatous polyposis (FAP) is represented by proctocolectomy with ileal pouch-anal anastomosis (IPAA). However, patients with UYC who have undergone IPAA are prone to develop several complications, which include surgery related/mecchanical complications; inflammatory or infectious disoreders; dysplasia or neoplasia; and systemic or metabolic disorders. Pouchitis, which is defined as the acute and/or chronic inflammation of the ileal reservoir, represent the most common long-term adverese sequela after IPAA. Gut microbiota play a pivotal role in the initiation and disease progression of pouchitis. Pouchitis can be clas…

Settore MED/12 - GastroenterologiaSettore MED/18 - Chirurgia Generalepouchitis ulcerative colitis inflammatory bowel diseas dysbiosis
researchProduct

Postoperative maintenance therapy for inflammatory bowel disease.

2006

. Curr Opin Gastroenterol. 2006 Jul;22(4):377-81. Postoperative maintenance therapy for inflammatory bowel disease. Cottone M, Orlando A, Modesto I. Department of General Medicine, Pneumology and Nutrition Clinic, Palermo University, Palermo, Italy. PURPOSE OF REVIEW: This review will highlight the knowledge gained from studies published in the year 2005 on maintenance treatment after surgery for inflammatory bowel diseases. RECENT FINDINGS: In Crohn's disease the role of smoking in increasing the risk of relapse and recurrence after surgery is confirmed. Ornidazole seems effective in reducing endoscopic recurrence and clinical relapse after surgery. Probiotics do not appear to be effective…

medicine.medical_specialtyAzathioprineInflammatory bowel diseaseEnteral NutritionMaintenance therapymedicineHumansIntensive care medicineDigestive System Surgical Procedurescrohn.post-operative.Postoperative CareCrohn's diseasebusiness.industryProbioticsGastroenterologyRetrospective cohort studyPouchitismedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisSurgeryAnti-Bacterial AgentsParenteral nutritionTreatment OutcomebusinessImmunosuppressive Agentsmedicine.drugCurrent opinion in gastroenterology
researchProduct

Infliximab and ulcerative colitis

2006

Expert Opin Biol Ther. 2006 Apr;6(4):401-8. Infliximab and ulcerative colitis. Cottone M, Mocciaro F, Modesto I. Università di Palermo, Istituto di Medicina Generale e Pneumologia, Via Trabucco 180, Palermo, Italy. dickens@tin.it Tumour necrosis factor (TNF)-alpha is an inflammatory cytokine that plays a main role in the inflammatory process underlying inflammatory bowel disease (IBD). Despite the fact that the cytokine profiles associated with ulcerative colitis (UC) and Crohn's disease (CD) are classically considered different (a Th2 pattern in UC and a Th1 pattern in CD), there are several evidences in vitro and in vivo that TNF-alpha has an important role in UC. For this reason, inflixi…

medicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryInflammatory bowel diseaseGastroenterologyGastrointestinal AgentsInternal medicineDrug Discoverymedicineinfliximab. ulcerative colitisHumansColitisPharmacologyGastrointestinal agentbusiness.industryAntibodies MonoclonalPouchitismedicine.diseaseUlcerative colitisInfliximabInfliximabCytokineImmunologyColitis UlcerativeTumor necrosis factor alphabusinessmedicine.drugExpert Opinion on Biological Therapy
researchProduct